Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Livselon is a multi-ingredient dietary supplement and organoprotector developed by Grand Medical Group. It is formulated as capsules and an oral solution (suspension) containing a combination of myo-inositol, alpha-lipoic acid, and herbal extracts from *Silybum marianum* (milk thistle), *Lespedeza capitata*, and *Urtica dioica* (stinging nettle). Livselon is designed to support renal and hepatic function, improve carbohydrate and lipid metabolism, and provide antioxidant protection. It is used as supportive therapy for conditions such as chronic kidney disease, liver and gallbladder dysfunction, metabolic syndrome, type 2 diabetes, and cardiovascular disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Livselon.